Genocury’s In Vivo CAR-T JY231 Shows Early Promise in Refractory Neurologic Autoimmune Diseases
A Chinese research team has reported encouraging early clinical results for JY231, an investigational lentiviral in vivo CD19 CAR-T therapy that generates therapeutic CAR-T cells directly inside the patient’s body, potentially eliminating two of…
Simnova Raises Nearly RMB 400 Million in Series B Financing to Advance CAR-NK and In Vivo CAR-T Platforms
Shanghai-based cell therapy developer Simnova has completed a nearly RMB 400 million (approximately US$55 million) Series B financing round, providing fresh capital to advance its lead off-the-shelf CAR-NK program SNC103 and its emerging in vivo CAR-T…
MagicRNA raises hundreds of millions of yuan in Series B financing to advance world’s first in vivo CAR-T therapy
Recently, Shenzhen MagicRNA Biotechnology Co., Ltd. (or MagicRNA) announced the completion of a Series B financing round of several hundred million yuan. This round was led by a fund under CICC Capital, co-led by Kangjun Capital , with participation from…